Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.12 USD
-0.03 (-2.18%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 81 - 100 ( 277 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
RGNX''s Suprachoroidal Gene Therapy Data Derisk Clearside''s SCS Injector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
RGX-314/wAMD Safety Requires Monitoring at Higher Doses; No Read Thru to CLS-AX
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
OASIS Trial Completes Cohort 2 Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
CLS-AX/wet AMD: Cohort 2 Dosed, Readout Expected by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
CLS-AX Data in Wet AMD Expected by YE & Adding to Multiple 2H21 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Expands XIPERE Licensing Agreement with Arctic Vision
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q2: XIPERE PDUFA on Oct 30, All Eyes on OASIS Cohort 2 Results by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Update - Key Value-Driving 2H21 Catalysts, Recommend Buying Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE Regulatory Approval Near-Term; 2Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Disrupting Drug Delivery to the Eye; Initiating at Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Adding CLS-AX to Model Due to Early Efficacy in wAMD & Raising PT to $15
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z